A Blueprint Medicines drug designed to address cancer that carries a certain genetic signature now has FDA approval, the latest targeted therapy to pass the regulatory bar this year.
The late Friday decision for pralsetinib (Gavreto) covers non-small cell lung cancer (NSCLC). The drug was designed to address cancers characterized by fusions or mutations of the RET gene, which produces a protein involved in cell signaling. Genetic abnormalities to the gene drive many types of cancer, including NSCLC. To be eligible for treatment, the RET alterations must first be detected by a genetic test. The drug from Cambridge, MA-based Blueprint… Read more »
UNDERWRITERS AND PARTNERS
